The first wave of chimeric antigen receptor T-cell (CAR-T) therapies – the CD19-targeted Kymriah from Novartis and Yescarta from Gilead – are now being established in the blood cancers acute lymphoblastic leukemia and diffuse large B-cell lymphoma, respectively, and attention has turned towards different CAR-T constructs and other cell therapy approaches that may show promise in the much larger solid tumor setting.
Over 90% of cancers arise from solid organs, but so far the development of effective cell therapies for these tumors has eluded developers. Solving this problem will be essential for cell therapy to move away from its current niche to become a mainstream treatment modality
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?